Affordable Access

Expression of Fas ligand in newly diagnosed childhood acute lymphoblastic leukemia.

Authors
  • Volm, M
  • Zintl, F
  • Sauerbrey, A
  • Koomägi, R
Type
Published Article
Journal
Anticancer research
Publication Date
Jan 01, 1999
Volume
19
Issue
4C
Pages
3399–3402
Identifiers
PMID: 10629626
Source
Medline
License
Unknown

Abstract

Immunocytochemistry was used to analyze the expression of the Fas ligand (FasL) in sixty-four children with newly diagnosed acute lymphoblastic leukemia (ALL). FasL expression was detected in 55 of 64 children (86%). Children with newly diagnosed ALL and FasL expression exhibited longer relapse-free and overall survival times under chemotherapy than did patients who did not express the Fas ligand. These data suggest that Fas/FasL mediated signaling may play a general role in the cytotoxicity of anticancer drugs.

Report this publication

Statistics

Seen <100 times